Effects of ketamine in normal and schizophrenic volunteers - PubMed

Clinical Trial

Effects of ketamine in normal and schizophrenic volunteers

A C Lahti et al. Neuropsychopharmacology. 2001 Oct.

Abstract

This study evaluates the effects of ketamine on healthy and schizophrenic volunteers (SVs) in an effort to define the detailed behavioral effects of the drug in a psychosis model. We compared the effects of ketamine on normal and SVs to establish the comparability of their responses and the extent to which normal subjects might be used experimentally as a model. Eighteen normal volunteers (NVs) and 17 SVs participated in ketamine interviews. Some (n = 7 NVs; n = 9 SVs) had four sessions with a 0.1-0.5 mg/kg of ketamine and a placebo; others (n = 11 NVs; n = 8 SVs) had two sessions with one dose of ketamine (0.3 mg/kg) and a placebo. Experienced research clinicians used the BPRS to assess any change in mental status over time and documented the specifics in a timely way. In both volunteer groups, ketamine induced a dose-related, short (<30 min) increase in psychotic symptoms. The scores of NVs increased on both the Brief Psychiatric Rating Scale (BPRS) psychosis subscale (p =.0001) and the BPRS withdrawal subscale (p =.0001), whereas SVs experienced an increase only in positive symptoms (p =.0001). Seventy percent of the patients reported an increase (i.e., exacerbation) of previously experienced positive symptoms. Normal and schizophrenic groups differed only on the BPRS withdrawal score. The magnitude of ketamine-induced changes in positive symptoms was similar, although the psychosis baseline differed, and the dose-response profiles over time were superimposable across the two populations. The similarity between ketamine-induced symptoms in SVs and their own positive symptoms suggests that ketamine provides a unique model of psychosis in human volunteers. The data suggest that the phencyclidine (PCP) model of schizophrenia maybe a more valid human psychosis/schizophrenia drug model than the amphetamine model, with a broader range of psychotic symptoms. This study indicates that NVs could be used for many informative experimental psychosis studies involving ketamine interviews.

Similar articles

• Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.

  Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA. Gouzoulis-Mayfrank E, et al. Pharmacopsychiatry. 2005 Nov;38(6):301-11. doi: 10.1055/s-2005-916185. Pharmacopsychiatry. 2005. PMID: 16342002 Clinical Trial.

• Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.

  Kleinloog D, Uit den Boogaard A, Dahan A, Mooren R, Klaassen E, Stevens J, Freijer J, van Gerven J. Kleinloog D, et al. J Psychopharmacol. 2015 Apr;29(4):401-13. doi: 10.1177/0269881115570082. Epub 2015 Feb 17. J Psychopharmacol. 2015. PMID: 25693889 Clinical Trial.

• [Effects of a subanaesthetic dose of ketamine on emotional and behavioral state in healthy subjects].

  Micallef J, Tardieu S, Gentile S, Fakra E, Jouve E, Sambuc R, Blin O. Micallef J, et al. Neurophysiol Clin. 2003 Jun;33(3):138-47. doi: 10.1016/s0987-7053(03)00028-5. Neurophysiol Clin. 2003. PMID: 12909392 Clinical Trial. French.

• [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

  Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L. Mechri A, et al. Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French.

• Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?

  Large CH. Large CH. J Psychopharmacol. 2007 May;21(3):283-301. doi: 10.1177/0269881107077712. J Psychopharmacol. 2007. PMID: 17591656 Review.

Cited by

• Ketamine Use for Cancer and Chronic Pain Management.

  Culp C, Kim HK, Abdi S. Culp C, et al. Front Pharmacol. 2021 Feb 2;11:599721. doi: 10.3389/fphar.2020.599721. eCollection 2020. Front Pharmacol. 2021. PMID: 33708116 Free PMC article. Review.

• Rethinking schizophrenia in the context of normal neurodevelopment.

  Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KM, Fillman SG, Rothmond DA, Sinclair D, Tiwari Y, Tsai SY, Weickert TW, Shannon Weickert C. Catts VS, et al. Front Cell Neurosci. 2013 May 15;7:60. doi: 10.3389/fncel.2013.00060. eCollection 2013. Front Cell Neurosci. 2013. PMID: 23720610 Free PMC article.

• The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices.

  Meier MA, Lemercier CE, Kulisch C, Kiss B, Lendvai B, Adham N, Gerevich Z. Meier MA, et al. Br J Pharmacol. 2020 Apr;177(7):1622-1634. doi: 10.1111/bph.14923. Epub 2020 Feb 19. Br J Pharmacol. 2020. PMID: 31722437 Free PMC article.

• Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

  Coyle JT. Coyle JT. Neurotox Res. 2006 Dec;10(3-4):221-33. doi: 10.1007/BF03033359. Neurotox Res. 2006. PMID: 17197372 Review.

• A review of the fetal brain cytokine imbalance hypothesis of schizophrenia.

  Meyer U, Feldon J, Yee BK. Meyer U, et al. Schizophr Bull. 2009 Sep;35(5):959-72. doi: 10.1093/schbul/sbn022. Epub 2008 Apr 11. Schizophr Bull. 2009. PMID: 18408229 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information